Results 151 to 160 of about 32,135 (260)

Differences in SARS‐CoV‐2 Antigen Persistence in Individuals With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A RECOVER‐Adult Cohort Study

Arthritis &Rheumatology, EarlyView.
Objective Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post–acute COVID‐19 outcomes, though whether individuals with SARDs have longer persistence of viral antigens after COVID‐19 has not been studied.
Naomi J. Patel, Zoe Swank, Jiaqi Wang, Xiaosong Wang, Lauren A. O'Keeffe, Madison Negron, Liya S. Getachew, Louise L. Hansen, Grace Qian, Alene A. Saavedra, Kevin T. Mueller, Natalie A. Davis, Kathleen M. M. Vanni, Sandria Savage, Julie S. Lam, Zachary S. Wallace, David R. Walt, Jeffrey A. Sparks, on behalf of RECOVER‐Adult   +18 more
wiley   +1 more source

African Vaccination Week as a catalyst for integrated services and immunisation equity: synthesis of implementation insights from countries in the WHO African Region

BMJ Public Health
Charles Shey Wiysonge, Sarah Wanyoike, Aschalew Teka Bekele, Crépin H Dadjo, Patricia E M Manga, Ado Mpia Bwaka, Yolande Vou Masembe   +6 more
doaj   +1 more source

Correction: Vaccine cold chain and understanding what underpins vaccine security for vaccine preventable diseases. [PDF]

BMJ Med
europepmc   +1 more source

Developing community-based surveillance systems for vaccine-preventable diseases: lessons learned from Indonesia. [PDF]

Glob Health Action
Sitorukmi G, Rusadi CP, Lazuardi L, Prasetyo S, Putri LP.   +4 more
europepmc   +1 more source

Pharmacokinetics, effectiveness and safety of certolizumab pegol in children and adolescents with active juvenile idiopathic arthritis: 9+‐year results from a multicenter, open‐label study

Arthritis &Rheumatology, Accepted Article.
Objective To assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients 2–17 years with active pcJIA and inadequate response ...
Hermine I Brunner, Lyudmila Grebenkina, Irina Nikishina, Ekaterina Alexeeva, Vyacheslav Chasnyk, Carlos Abud‐Mendoza, Nadina Rubio‐Pérez, Heinrike Schmeling, María del Rocio Maldonado‐Velázquez, Diane Brown, Andrew Zeft, Esi Morgan, C. Egla Rabinovich, Daniel Kingsbury, Hulya Bukulmez, Beth Gottlieb, Thomas Griffin, Lisa Imundo, Stacey Tarvin, Earl Silverman, Laura Shaughnessy, Saori Shimizu, Paulette Williams, Rocío Lledó‐García, Gauri Utturkar, Baran Ufuktepe, Alberto Martini, Daniel Lovell, Nicolino Ruperto   +28 more
wiley   +1 more source

Immunoinformatics‐Based Design of a Multi‐Epitope Vaccine Targeting a Conserved Copper–Associated Protein in Neisseria gonorrhoeae

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Neisseria gonorrhoeae poses an urgent public health challenge due to rapidly increasing antimicrobial resistance and the absence of an effective vaccine. Targeting conserved bacterial pathways involved in essential physiological processes may provide new opportunities for vaccine antigen discovery.
Sinethemba H. Yakobi, Uchechukwu U. Nwodo   +1 more
wiley   +1 more source

Parental vaccine refusal, non-vaccinated children, and outbreaks of Vaccine-Preventable Diseases (VPDs) in Europe: a systematic review of aetiology and risk. [PDF]

BMC Public Health
Baiocchi C, Bhardwaj M.
europepmc   +1 more source

Targeting Amastigote and Trypomastigote Phases: Multi‐Epitope Vaccine Strategy Against Trypanosoma cruzi

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Effective vaccines against Trypanosoma cruzi, the causative agent of Chagas disease, are urgently needed. Here, we report the design and in silico validation of a novel multiepitope vaccine construct targeting the key surface proteins ASP‐2 and gp82. Using a comprehensive immunoinformatics pipeline, we identified and selected 38 potent T‐cell (
Maria Karolaynne da Silva, Caio Patrício de Souza Sena, Davi Serradella Vieira, Magdi E. A. Zaki, Leow Chiuan Yee, Shahina Akter, Umberto Laino Fulco, Jonas Ivan Nobre Oliveira, João Firmino Rodrigues‐Neto   +8 more
wiley   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

A Multiplex Bead Serology Panel For Vaccine-Preventable Diseases Using Dried Blood Spots. [PDF]

Risk Manag Healthc Policy
Olivo PD, Ghatak S, Rasch R.
europepmc   +1 more source